Pulmonary Hypertension and Erythropoietin | Zendy

Michele Buemi | Zendy; Massimino Senatore | Zendy; Giovanna Gallo | Zendy; Eleonora Crascì | Zendy; S. Campo | Zendy; Alessio Sturiale | Zendy; Giuseppe Coppolino | Zendy; Davide Bolignano | Zendy; N Frisina | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pulmonary Hypertension and Erythropoietin

Author(s) -

Michele Buemi,

Massimino Senatore,

Giovanna Gallo,

Eleonora Crascì,

S. Campo,

Alessio Sturiale,

Giuseppe Coppolino,

Davide Bolignano,

N Frisina

Publication year - 2007

Publication title -

kidney and blood pressure research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.806

H-Index - 51

eISSN - 1423-0143

pISSN - 1420-4096

DOI - 10.1159/000104443

Subject(s) - erythropoietin , medicine , vasodilation , pulmonary hypertension , blood pressure , dialysis , hemodialysis , cardiology , vascular smooth muscle , endocrinology , hypoxia (environmental) , lung , smooth muscle , chemistry , organic chemistry , oxygen

Numerous uremic patients on hemodialysis have pulmonary hypertension attributable to the presence of arteriovenous fistulas, vascular calcification, and endothelial dysfunction due to alterations in the balance between vasoconstrictive and vasodilatory substances. For these reasons, the effects of recombinant human erythropoietin, a drug widely used in patients on dialysis, on the pulmonary circulation were studied. Some authors maintain that recombinant human erythropoietin has an antihypertensive effect, while others have observed that this hormone induces a reduction in pulmonary arterial pressure due to its vasoactive and stimulatory effects on endothelial and smooth muscle cell precursors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research